Cetuximab in the treatment of squamous cell carcinoma of the head and neck

Expert Review of Anticancer Therapy

Volumn 11, Issue 4, 2011, Pages 511-524

  Specenier, Pol ^a   Vermorken, Jan B ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

cetuximab; head and neck cancer; locoregionally advanced disease; recurrent and metastatic disease; SCCHN

Indexed keywords

AMIFOSTINE; BENDAMUSTINE; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; HYDROXYUREA; PACLITAXEL; PEMETREXED; PLACEBO;

ACNE; ANEMIA; ANOREXIA; ANXIETY; ARTICLE; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHILL; CONSTIPATION; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; COUGHING; DEHYDRATION; DERMATITIS; DIARRHEA; DISEASE SEVERITY; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPHAGIA; DYSPNEA; ECZEMA; FEBRILE NEUTROPENIA; FEVER; HEAD AND NECK CARCINOMA; HEADACHE; HEART DISEASE; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; INFECTION; INSOMNIA; LEUKOPENIA; LIVER FAILURE; LIVER TOXICITY; MAINTENANCE THERAPY; MOUTH INFLAMMATION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; ODYNOPHAGIA; ORAL MUCOSAL DISEASE; OROPHARYNX CANCER; OVERALL SURVIVAL; PAIN; PARONYCHIA; PHARYNGITIS; PNEUMONIA; PRURITUS; QUALITY ADJUSTED LIFE YEAR; RADIATION DERMATITIS; RADIATION DOSE; RASH; RECOMMENDED DRUG DOSE; SEPSIS; SIDE EFFECT; SPEECH DISORDER; SPUTUM; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TASK PERFORMANCE; TASTE DISORDER; THROMBOCYTOPENIA; THRUSH; TUMOR BLEEDING; UNSPECIFIED SIDE EFFECT; VOICE CHANGE; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASMS, SQUAMOUS CELL; ORGANOPLATINUM COMPOUNDS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79955083789     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.20     Document Type: Article

References (90)

1. Nasman A, Attner P, Hammarstedt L et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int. J. Cancer 125(2), 362-366 (2009).
2. Marur S, D'souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 11(8), 781-789 (2010).
3. Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. 64(15), 5355-5362 (2004). (Pubitemid 39006556)
4. Saleh MN, Raisch KP, Stackhouse MA et al. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother. Radiopharm. 14(6), 451-463 (1999). (Pubitemid 30029793)
5. Zhang N, Erjala K, Kulmala J et al. Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro. Radiother. Oncol. 92(3), 388-392 (2009).
6. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 53(19), 4637-4642 (1993). (Pubitemid 23304392)
7. Dirks NL, Nolting A, Kovar A, Meibohm B. Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. J. Clin. Pharmacol. 48(3), 267-278 (2008). (Pubitemid 351257778)
8. Baselga J, Pfister D, Cooper MR et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 18(4), 904-914 (2000). (Pubitemid 30106623)
9. Shin DM, Donato NJ, Perez-Soler R et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res. 7(5), 1204-1213 (2001). (Pubitemid 32708671)
10. Robert F, Ezekiel MP, Spencer SA et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol. 19(13), 3234-3243 (2001). (Pubitemid 32591441)
11. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354(6), 567-578 (2006). (Pubitemid 43209104)
12. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a Phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 11(1), 21-28 (2010).
13. Curran D, Giralt J, Harari PM et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J. Clin. Oncol. 25(16), 2191-2197 (2007). (Pubitemid 46954642)
14. No authors listed. StatBite: radiation therapy plus cetuximab: skin reactions from 71 head and neck cancer patients from 11 institutions in Europe. J. Natl Cancer Inst. 102(2), 75 (2010).
15. Azad A. Severe cutaneous toxicity following treatment with radiotherapy and cetuximab: a case report. Cases J. 2(1), 25 (2009).
16. Billan S, Abdah-Bortnyak R, Kuten A. Severe desquamation with skin necrosis: a distinct pattern of skin toxicity secondary to head and neck irradiation with concomitant cetuximab. Isr. Med. Assoc. J. 10(3), 247 (2008).
17. Bolke E, Gerber PA, Lammering G et al. Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab. Strahlenther. Onkol. 184(2), 105-110 (2008). (Pubitemid 351231657)
18. Budach W, Bolke E, Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N. Engl. J. Med. 357(5), 514-515 (2007). (Pubitemid 47204904)
19. Giro C, Berger B, Bolke E et al. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother. Oncol. 90(2), 166-171 (2009).
20. Janssens GO, van Herpen CM. [Diagnostic image; a man with severe radiation dermatitis]. Ned. Tijdschr. Geneeskd. 153, B413 (2009).
21. Koutcher LD, Wolden S, Lee N. Severe radiation dermatitis in patients with locally advanced head and neck cancer treated with concurrent radiation and cetuximab. Am. J. Clin. Oncol. DOI: 10.1097/ COC.0b013e318193125c (2009) (Epub ahead of print).
22. Mydin AR, Armstrong JG. Acneiform rash secondary to cetuximab plus head and neck radiotherapy. Radiother. Oncol. 85(1), 171 (2007). (Pubitemid 47562579)
23. Pryor DI, Porceddu SV, Burmeister BH et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother. Oncol. 90(2), 172-176 (2009).
24. Studer G, Brown M, Salgueiro EB et al. Grade 3/4 dermatitis in head and neck cancer patients treated with concurrent cetuximab and IMRT. Int. J. Radiat. Oncol. Biol. Phys. DOI: 10.1016/j. ijrobp.2010.05.018 (2010) (Epub ahead of print).
25. Vano-Galvan S, de las HE, Harto A, Jaen P. Severe cutaneous toxicity during concomitant radiotherapy and cetuximab treatment of head and neck cancer. Eur. J. Dermatol. 18(4), 471-472 (2008). (Pubitemid 352031870)
26. Waris W, Naik S, Idrees I et al. Severe cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancer. Cutan. Ocul. Toxicol. 28(1), 41-44 (2009).
27. Walsh L, Gilham C, Dunne M et al. Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LASCCHN).Radiother. Oncol. 98(1), 38-41 (2011).
28. Pignon JP, le Maître A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother. Oncol. 92(1), 4-14 (2009).
29. Koutcher L, Sherman E, Fury M et al. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. DOI: 10.1016/j. ijrobp.2010.07.008 (2010) (Epub ahead of print).
30. Pfister DG, Su YB, Kraus DH et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot Phase II study of a new combined-modality paradigm. J. Clin. Oncol. 24(7), 1072-1078 (2006). (Pubitemid 46638804)
31. RTOG 0522: a randomized Phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab (followed by surgery for selected patients) for stage III and IV head and neck carcinomas. Clin. Adv. Hematol. Oncol. 5(2), 79-81 (2007).
32. Kuhnt T, Sandner A, Wendt T et al. Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck. Ann. Oncol. 21(11), 2284-2289 (2010).
33. Argiris A, Heron DE, Smith RP et al. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J. Clin. Oncol. 28(36), 5294-5300 (2010).
34. Koukourakis MI, Tsoutsou PG, Karpouzis A et al. Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study. Int. J. Radiat. Oncol. Biol. Phys. 77(1), 9-15 (2010).
35. Merlano M, Russi E, Benasso M et al. Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a Phase II clinical study. Ann. Oncol. 22(3), 712-717 (2010).
36. Birnbaum A, Dipetrillo T, Rathore R et al. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis. Am. J. Clin. Oncol. 33(2), 144-147 (2010).
37. Kao J, Genden EM, Gupta V et al. Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer. Cancer 117(2), 318-326 (2011).
38. Licitra L, Bergamini C, Olmi P, Soldatenkova V, Ameryckx S, Russo F. Phase I study of concurrent pemetrexed, cetuximab and radiation therapy with or without cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck. Ann. Oncol. 21(8s), 1025 (2010).
39. Gibson MK, Smith RP, Heron DE et al. Phase I trial of pemetrexed, cetuximab, and concurrent radiotherapy (RT) in head and neck cancer (HNC).J. Clin. Oncol. 26(Suppl), 2540 (2008).
40. Kotsakis A, Heron DE, Kubicek GJ et al. Phase II randomized trial of radiotherapy (RT), cetuximab (E), and pemetrexed (Pem) with or without bevacizumab (B) in locally advanced squamous cell carcinoma of the head and neck (SCCHN).J. Clin. Oncol. 28(15s), TPS264 (2010).
41. Bernier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 350(19), 1945-1952 (2004). (Pubitemid 38580197)
42. Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 350(19), 1937-1944 (2004).
43. Kies MS, Harris J, Rotman MZ et al. Phase II randomized trial of postoperative chemoradiation plus cetuximab for high-risk squamous cell carcinoma of the head and neck (RTOG 0234).Int. J. Radiat. Oncol. Biol. Phys. 75(3), S14-S15 (2009).
44. Mesia R, Rueda A, Vera R et al. Is there a role for adjuvant cetuximab after radiotherapy (RT) plus cetuximab in patients (pts) with locally advanced squamous cell carcinoma of the oropharynx? A Phase II randomized trial. J. Clin. Oncol. 28(15s), 5534 (2010).
45. Gregoire V, Lefebvre JL, Licitra L, Felip E. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl. 5), v184-v186 (2010).
46. Specenier PM, Vermorken JB. Neoadjuvant chemotherapy in head and neck cancer: should it be revisited? Cancer Lett. 256(2), 166-177 (2007). (Pubitemid 47418352)
47. Pointreau Y, Garaud P, Chapet S et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J. Natl Cancer Inst. 101(7), 498-506 (2009).
48. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N. Engl. J. Med. 357(17), 1705-1715 (2007). (Pubitemid 350005152)
49. Vermorken JB, Remenar E, van HC et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N. Engl. J. Med. 357(17), 1695-1704 (2007). (Pubitemid 350005151)
50. Haddad RI, Tishler RB, Norris C et al. Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. J. Clin. Oncol. 27(27), 4448-4453 (2009).
51. Dietz A, Flentje M, Hagen R et al. Docetaxel, cisplatin (TP), and radiation with or without cetuximab in advanced larynx carcinoma (DeLOS II trial).J. Clin. Oncol. 28(15s), TPS265 (2010).
52. Mesia R, Vasquez S, Grau JJ et al. A single-arm Phase II trial to evaluate the combination of cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (TPF) as induction cehmotherapy in patients with unresectable SCCHN. J. Clin. Oncol. 27(15s), 6015 (2009).
53. Wanebo H, Ghebremichael MS, Burtness B, Ridge JA, Spencer S, Rosen FR. Phase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68-72 Gy for stage III/IV head and neck squamous cancer: primary site organ preservation and disease control at 2 years (ECOG E2303).J. Clin. Oncol. 28(15s), 5513 (2010).
54. Kies MS, Holsinger FC, Lee JJ et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a Phase II prospective trial. J. Clin. Oncol. 28(1), 8-14 (2010).
55. Kuperman DI, Ley J, Nussenbaum B et al. Clinical response rate at primary tumor site by WHO criteria following an induction chemotherapy regimen of weekly nanoparticle albumin-bound (nab-) paclitaxel and cetuximab with every 3 week cisplatin and 5-FU in patients with locally advanced nonmetastatic head and neck squamous cell carcinoma (HNSCC).J. Clin. Oncol. 28(15s), e16028 (2010).
56. Ferris RL, Heron DE, Kim S et al. Induction docetaxel, cisplatin, and cetuximab (TPE) followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locoregionally advanced head and neck cancer (HNC): mature results with HPV analysis. J. Clin. Oncol. 28(15s), 5515 (2010).
57. Mercke C, Wickart-Johansson G, Sjodin H, Adell G, Nyman J, Haugen H. Upfront chemotherapy and accelerated radiotherapy with EGFR inhibition for locally advanced inoperable head and neck cancer. J. Clin. Oncol. 27(15), 6040 (2009).
58. Jordan W, Wildfang I, Welkoborsky H et al. TPF induction- radioimmunochemotherapy for the treatment of advanced head and neck cancer. J. Clin. Oncol. 28(15s), 5514 (2010).
59. Mesia R, Vazquez S, Grau JJ et al. A multicentre Phase II trial to evaluate the combination of cetuximab plus TPF (docetaxel, cisplatin and fluorouracil) as induction chemotherapy followed by cetuximab plus accelerated radiotherapy with concomitant boost in patients with unresectable locally advanced squamous cell carcinoma of the head and neck. Ann. Oncol. 21(Suppl 8), 1023P (2010).
60. Lefebvre J, Pointreau Y, Rolland F et al. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): preliminary results of the randomized Phase II TREMPLIN study. J. Clin. Oncol. 27(15), 6010 (2009).
61. Zwicker F, Roeder F, Thieke C et al. IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer. Strahlenther. Onkol. 187(1), 32-38 (2010).
62. Heron DE, Rwigema JC, Gibson MK et al. Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control Study. Am. J. Clin. Oncol. DOI: 10.1097/ COC.0b013e3181dbb73e (2010) (Epub ahead of print).
63. Rusthoven KE, Feigenberg SJ, Raben D et al. Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 78(4), 1020-1025 (2010).
64. Balermpas P, Hambek M, Seitz O, Rödel C, Weiss C. Combined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck. Strahlenther. Onkol. 185(12), 775-781 (2009).
65. Vermorken JB, Trigo J, Hitt R et al. Open-label, uncontrolled, multicenter Phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J. Clin. Oncol. 25(16), 2171-2177 (2007). (Pubitemid 46954639)
66. Baselga J, Trigo JM, Bourhis J et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol. 23(24), 5568-5577 (2005).
67. Herbst RS, Arquette M, Shin DM et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J. Clin. Oncol. 23(24), 5578-5587 (2005).
68. Knoedler MK, Gauler T, Matzdorff A et al. Multicenter Phase II study of cetuximab plus docetaxel in 84 patients with recurrent or metastatic, platinum-pretreated SCCHN. J. Clin. Oncol. 27(15), 6048 (2009).
69. Zakaria H, Jordan WO, Wildfang I et al. Cetuximab in combination with bendamustine as an alternative therapeutic option for recurrent head and neck cancer. Ann. Oncol. 21(8s), 1034 (2010).
70. Bourhis J, Rivera F, Mesia R et al. Phase I/ II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 24(18), 2866-2872 (2006). (Pubitemid 46630587)
71. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359(11), 1116-1127 (2008).
72. Licitra L, Mesia R, Rivera F et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann. Oncol. DOI: 10.1093/annonc/mdq588 (2010) (Epub ahead of print).
73. Mesia R, Rivera F, Kawecki A et al. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann. Oncol. 21(10), 1967-1973 (2010).
74. Burtness B. Cetuximab and cisplatin for chemotherapy-refractory squamous cell cancer of the head and neck. J. Clin. Oncol. 23(24), 5440-5442 (2005).
75. Rozzi A, Lenci G, Nardoni C et al. Weekly regimen of paclitaxel- carboplatin- cetuximab as first-line chemotherapy in patients with platinum-resistant recurrent or metastatic squamous cell carcinoma of head and neck: results of a Phase II study. Ann. Oncol. 21(8s), 1035 (2010).
76. Hitt R, Irigoyen A, Nunez J et al. Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/ recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC).J. Clin. Oncol. 25 (18s), 6012 (2007).
77. Vermorken B, Stöhlmacher J, Davidenko I et al. Primary efficacy and safety results of SPECTRUM, a Phase 3 trial in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without panitumumab. Ann. Oncol. 21(Suppl 8), LBA26 (2010).
78. Machiels JH, Subramanian S, Ruzsa A et al. An open-label, randomized, Phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFR) antibody, versus best supportive care, in patients with noncurable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based chemotherapy (ZALUTE).J. Clin. Oncol. 28(18s), LBA5506 (2010).
79. Gibson MK, Kies M, Kim S et al. Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma: an updated report. J. Clin. Oncol. 27(15), 6049 (2009).
80. Seiwert TY, Fayette J, Del Campo JM et al. Updated results of a randomized, open-label Phase II study exploring BIBW 2992 versus cetuximab in patients with platinum-refractory metastatic/reciurrent head and neck cancer (SCCHN).Ann. Oncol. 21(Suppl. 8), 1010PD (2010).
81. Specenier PM, Vermorken JB. Targeted therapies in head and neck cancer. Target. Oncol. 2(2), 73-88 (2007).
82. Griffin S, Walker S, Sculpher M et al. Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck. Health Technol. Assess. 13(Suppl. 1), 49-54 (2009).
83. Brown B, Diamantopoulos A, Bernier J et al. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. Value. Health 11(5), 791-799 (2008).
84. Sambrook J, Levy AR, Johnston KM et al. Cost-effectiveness of cetuximab for the first-line treatment of squamous cell carcinoma of the head and neck (SCCHN) in Canada. J. Clin. Oncol. 27(15), e17000 (2009).
85. Bagust A, Greenhalgh J, Boland A et al. Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal. Pharmacoeconomics. 28(6), 439-448 (2010).
86. Greenhalgh J, Bagust A, Boland A et al. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Health Technol. Assess. 13(Suppl. 3), 49-54 (2009).
87. Segaert S, Van CE. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann. Oncol. 16(9), 1425-1433 (2005). (Pubitemid 41222414)
88. Segaert S, Tabernero J, Chosidow O et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J. Dtsch. Dermatol. Ges. 3(8), 599-606 (2005). (Pubitemid 41647826)
89. Tan EH, Chan A. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors. Ann. Pharmacother. 43(10), 1658-1666 (2009).
90. Bernier J, Bonner J, Vermorken JB et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann. Oncol. 19(1), 142-149 (2008).